What the EU’s Elfabrio dosing update means for Fabry disease treatment burden
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.
What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs
Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.
Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.
Zealand Pharma advances petrelintide toward Phase 3 as obesity treatment competition intensifies
Zealand Pharma advances petrelintide toward Phase 3 after strong Phase 2 obesity trial results. Discover what this means for the evolving weight-loss drug market.
Alnylam Pharmaceuticals taps Tenaya Therapeutics to uncover new cardiovascular RNAi drug targets
Alnylam Pharmaceuticals partners with Tenaya Therapeutics to discover RNAi targets for cardiovascular disease. Read the analysis behind this biotech collaboration.
How Persevere Therapeutics plans to reposition misetionamide in a crowded ovarian cancer pipeline
Persevere Therapeutics launches misetionamide trial in platinum-resistant ovarian cancer. Discover what this dual-pathway strategy could mean for treatment.
Psyence Biomedical Ltd. advances natural psilocybin development with Phase IIb cancer distress trial
Psyence Biomedical Ltd. advances natural psilocybin therapy in a Phase IIb cancer distress trial. Explore what this means for psychedelic medicine development.
Insight Molecular Diagnostics builds regulatory case for GraftAssureDx kidney transplant test
Insight Molecular Diagnostics advances GraftAssureDx toward FDA submission. Discover what this means for transplant rejection testing and dd-cfDNA diagnostics.
Is Propanc Biopharma’s PRP proenzyme platform a credible challenger in the pancreatic oncology market?
Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.